Levofenfluramine: Difference between revisions
CSV import |
No edit summary |
||
| Line 25: | Line 25: | ||
{{stub}} | {{stub}} | ||
== Levofenfluramine == | == Levofenfluramine == | ||
<gallery> | <gallery> | ||
Latest revision as of 00:34, 17 March 2025
Levofenfluramine is a drug that was previously used as an appetite suppressant, but was withdrawn from the market due to its potential to cause pulmonary hypertension and heart valve disease. It is the levorotatory enantiomer of the amphetamine derivative fenfluramine.
History[edit]
Levofenfluramine was first synthesized in the 1970s and was marketed as an appetite suppressant. However, it was withdrawn from the market in the late 1990s due to concerns about its potential to cause pulmonary hypertension and heart valve disease.
Pharmacology[edit]
Levofenfluramine acts as a serotonin releasing agent. It increases the concentration of serotonin in the brain, which leads to a decrease in appetite. However, it also has the potential to cause pulmonary hypertension and heart valve disease.
Side Effects[edit]
The most common side effects of levofenfluramine include dizziness, dry mouth, insomnia, and constipation. However, the most serious side effects are pulmonary hypertension and heart valve disease.
Withdrawal from the Market[edit]
Levofenfluramine was withdrawn from the market in the late 1990s due to concerns about its potential to cause pulmonary hypertension and heart valve disease. This decision was based on several studies that showed a significant increase in the risk of these conditions in people who used the drug.
